2,5-Dioxopyrrolidin-1-yl 3-(2-(2-(prop-2-yn-1-yloxy)ethoxy)ethoxy)propanoate

Catalog No. :
ACKOPX587
CAS No. :
1428629-71-3
Molecular Formula :
C14H19NO7
Molecular Weight :
313.31

IUPAC Name:Propargyl-PEG-NHS ester, MW 2,000

2,5-Dioxopyrrolidin-1-yl 3-(2-(2-(prop-2-yn-1-yloxy)ethoxy)ethoxy)propanoate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g97%$101.00Login to see priceIn stockIn stock
5g97%$254.00Login to see priceIn stockIn stock
25g97%$891.00Login to see priceIn stockIn stock

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2,5-Dioxopyrrolidin-1-yl 3-(2-(2-(prop-2-yn-1-yloxy)ethoxy)ethoxy)propanoate
IUPAC NamePropargyl-PEG-NHS ester, MW 2,000
MDL No.MFCD23726610
Molecular FormulaC14H19NO7
Molecular Weight313.31
SMILESO=C(ON1C(CCC1=O)=O)CCOCCOCCOCC#C
InChI KeyYDRPXORAOIYIGV-UHFFFAOYSA-N
SynonymAKOS030630034 | Propargyl-PEG2-CH2CH2COONHS | Propargyl-PEG3-NHS ester | HY-126974 | (2,5-dioxopyrrolidin-1-yl) 3-[2-(2-prop-2-ynoxyethoxy)ethoxy]propanoate | ZB0909 | Alkyne-PEG3-NHS | SCHEMBL17776277 | 1428629-71-3 | AS-77059 | DTXSID101123098 | 2,5-Dio
CAS No.1428629-71-3
PubChem CID77078448

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACKOPX587 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACKOPX587 route product structure diagram
    ACKOPX5871428629-71-3 In Stock
Inquiry

2. ACKOPX587 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACKOPX587 route product structure diagram
    ACKOPX5871428629-71-3 In Stock
Inquiry

Comments (0)